|Bid||0.90 x 2500|
|Ask||1.15 x 500|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
"The past year has been a period of transformational change for the company," said Michael F. Cola, President and Chief Executive Officer of Aevi Genomic Medicine. In conjunction with the corporate name change, the company will trade on the NASDAQ Global Market under the new ticker symbol "GNMX".
You probably know from experience that there is not as much information on small-cap companies as there is on large companies. Of course, this makes it really hard and difficult for individual investors to make proper and accurate analysis of certain small-cap companies. However, well-known and successful hedge fund investors like Carl Icahn and George […]
Medgenics, Inc. today announced that Michael F. Cola, President and Chief Executive Officer, will present at the 28th Annual Piper Jaffray Healthcare Conference in New York, NY on Wednesday, November 30, ...
Medgenics, Inc. today announced that Michael F. Cola, President and Chief Executive Officer, will present at the Jefferies London Healthcare Conference in London, UK on Thursday, November 17, 2016 at 10:40 ...
Medgenics, Inc. will host a conference call and live audio webcast on Thursday, November 3, 2016 at 8:30 a.m. EST to report financial results for the third quarter ended September 30, 2016 and discuss ...